Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

Both tirzepatide and semaglutide had safety profiles consistent with those in previous trials. 13,14,18–20 As typically observed with incretin-based therapies, gastrointestinal adverse events ...

At 72 weeks, participants treated with tirzepatide achieved a mean body weight reduction of 20.2%, compared to 13.7% with semaglutide, a statistically and clinically significant difference.

Tirzepatide works similarly to semaglutide but also targets an additional receptor—GIP —explains Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center ...

In the study, patients were randomized to either tirzepatide 5 mg, 10 mg, or 15 mg vs semaglutide 1 mg. The mean age was 56.6 years, 53% were women, mean A1c was 8.3%, and mean BMI was 34.2.

My InsiderPatients taking a once-weekly injection of tirzepatide, currently available to diabetes patients under the brand name Mounjaro, lost more than 24% of their body weight, on average, by ...

Is tirzepatide or semaglutide better for weight loss? “In studies, tirzepatide is better for weight loss,” Dr. Shah says. But he stresses that everyone responds to the medications differently.

Tirzepatide was approved by the FDA for adults with diabetes in May 2022, under the name Mounjaro. Like semaglutide products, tirzepatide is used to control blood sugar levels, and is administered ...

In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At ...